Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Switching from natalizumab to fingolimod: an observational study

(2013) A. P. Sempere et al.   ACTA NEUROLOGICA SCANDINAVICA

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

(2012) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

(2012) L Daelman et al.   Multiple Sclerosis Journal

Time to talk about timing – when to start, stop and change anti-migratory drugs in MS

(2012) Olaf Stüve et al.   Multiple Sclerosis Journal

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

(2012) A Laroni et al.   Multiple Sclerosis Journal

Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis

(2012) Andrea Harrer et al.   PLoS One

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

(2011) Theo Rispens et al.   Multiple Sclerosis Journal

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY